Creating J&J's Cardiology Franchise: An Interview with Marv Woodall
Executive Summary
In this interview, Marv Woodall, the architect of Johnson & Johnson's cardiology business, reflects on the ups and downs of building a stent business, integrating a hostile takeover, and why--despite all their success--stents have not met their original goal.
You may also be interested in...
Prescient Medical's Dual Approach to Vulnerable Plaque
Vulnerable plaque caught investors' and entrepreneurs' attention several years ago as the mysterious cause of more than half of all cases of sudden cardiac death, most of which occurs in people with no history of heart disease. Several companies were launched and much money invested with little to show for it. One major problem: vulnerable plaque requires new tools both to diagnose and treat the condition, which proved to be bigger hurdles than most start-ups can overcome. Prescient was launched by an experienced device management team and is applying Raman spectroscopy, to coronary disease as the basis of its diagnostic tool, and is using a shield-not a stent-for its therapeutic device.
EU Business News: Biofarma Gets New PE Owners; Montefarmaco Strikes Ipsen Deal; Stada Expands Production Network
Round-up of the latest European consumer health market news: Private-equity firm Ardian acquires Italian supplements and cosmetics manufacturer Biofarma; Montefarmaco OTC strikes deal with Ipsen for GI lines; and Stada expands its production network with new Romania site.
FDA Publishes Raft Of Guidances To Promote Competition
The US FDA has published a raft of guidances on ANDA submissions and labeling updates as well as information requests and discipline review letters.